

# PATIENT INFORMATION AND CONSENT FOR HAT® THERAPY (Hemoadsorption Therapy)

Valid as of 01 May 2025



## 1. Purpose of the Therapy

HAT® (Hemoadsorption Therapy) is an innovative extracorporeal blood purification method designed to remove toxins, inflammatory mediators (cytokines), heavy metals, environmental pollutants, and endogenous waste products such as bilirubin and myoglobin from the bloodstream. The goal of this therapy is to stabilize immune function, alleviate chronic symptoms, and support mitochondrial activity and cellular metabolism.

The procedure takes approximately 3 – 4 hours. Through a central venous catheter (Sheldon catheter), your blood is circulated through special adsorber filters, cleansed, and then returned to your body.

## 2. Indications

HAT® may be considered for the following medical conditions:

- Long-COVID and ME/CFS (Chronic Fatigue Syndrome)
- Chronic inflammatory diseases
- Autoimmune conditions
- Environmental and heavy metal toxicity
- Liver, lung, kidney, and rheumatic disorders

## 3. Off-Label Use and Regulatory Notice

Please note that this therapy is classified as an **off-label treatment**. This means that:

- The underlying method and the CE-certified equipment and filters used (Jafron HA series, Future F20 machine) are approved for medical use,
- However, their use for the above-mentioned chronic conditions (such as Long-COVID or ME/CFS) has not been specifically authorized by the Swiss regulatory authority (Swissmedic).

The treatment is based on international clinical experience, scientific studies, and its application in critical care and emergency medicine. Nonetheless, from a regulatory standpoint, this is considered an **individual therapeutic trial outside the formally approved indications**.

# PATIENT INFORMATION AND CONSENT FOR HAT® THERAPY (Hemoadsorption Therapy)

Valid as of 01 May 2025



## 4. Risks and Possible Side Effects

Despite all precautions, complications or adverse reactions may occur during or after treatment. These may include:

- Circulatory reactions (e.g., drop in blood pressure)
- Bleeding due to anticoagulation (Heparin administration)
- Catheter-related complications (infection, thrombosis)
- Reactions to sedatives or infusions
- Fatigue or weakness after the procedure

All treatments are supervised by qualified medical professionals. Our trained nursing staff are licensed and authorized to insert central venous catheters in accordance with regional regulations.

## 5. Alternative Treatment Options

At present, there is no officially approved curative therapy for Long-COVID or ME/CFS. Conventional medicine focuses on symptomatic management (e.g., pain relief, corticosteroids, physical therapy). HAT® is offered as an **adjunctive and individualized therapy**.

## 6. Informed Consent

By signing this document, you confirm:

- that you have received comprehensive information about the nature, purpose, risks and experimental (off-label) status of HAT® therapy,
- that all your questions have been answered in a clear and understandable manner,
- and that you voluntarily consent to the proposed treatment.

## Patient Information

\_\_\_\_\_  
Name

\_\_\_\_\_  
Date of Birth

\_\_\_\_\_  
Date of Treatment

\_\_\_\_\_  
Signature – Patient

\_\_\_\_\_  
Location/Date

\_\_\_\_\_  
Signature – Physician